CN103169984B - N末端聚唾液酸化 - Google Patents

N末端聚唾液酸化 Download PDF

Info

Publication number
CN103169984B
CN103169984B CN201310022631.9A CN201310022631A CN103169984B CN 103169984 B CN103169984 B CN 103169984B CN 201310022631 A CN201310022631 A CN 201310022631A CN 103169984 B CN103169984 B CN 103169984B
Authority
CN
China
Prior art keywords
insulin
polysaccharide
protein
compositions
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310022631.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103169984A (zh
Inventor
S·杰因
张荣升
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Publication of CN103169984A publication Critical patent/CN103169984A/zh
Application granted granted Critical
Publication of CN103169984B publication Critical patent/CN103169984B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
CN201310022631.9A 2006-07-25 2007-07-25 N末端聚唾液酸化 Expired - Fee Related CN103169984B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117830.7 2006-07-25
EP06117830 2006-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800337418A Division CN101511391B (zh) 2006-07-25 2007-07-25 N末端聚唾液酸化

Publications (2)

Publication Number Publication Date
CN103169984A CN103169984A (zh) 2013-06-26
CN103169984B true CN103169984B (zh) 2016-08-03

Family

ID=37397314

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310022631.9A Expired - Fee Related CN103169984B (zh) 2006-07-25 2007-07-25 N末端聚唾液酸化
CN2007800337418A Expired - Fee Related CN101511391B (zh) 2006-07-25 2007-07-25 N末端聚唾液酸化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800337418A Expired - Fee Related CN101511391B (zh) 2006-07-25 2007-07-25 N末端聚唾液酸化

Country Status (10)

Country Link
US (22) US8299015B2 (enExample)
EP (6) EP2043692B1 (enExample)
JP (14) JP2009544680A (enExample)
KR (1) KR101400105B1 (enExample)
CN (2) CN103169984B (enExample)
AT (1) ATE467642T1 (enExample)
DE (1) DE602007006492D1 (enExample)
ES (5) ES2344670T3 (enExample)
RU (1) RU2432175C2 (enExample)
WO (4) WO2008012540A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US20110159130A1 (en) 2007-02-28 2011-06-30 Sanjay Jain Reduction of endotoxin in polysialic acids
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
MX2011004195A (es) * 2008-10-20 2011-09-27 Usv Ltd Un proceso mejorado para la pegilacion de proteinas.
CA2742064A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
WO2011156242A2 (en) * 2010-06-11 2011-12-15 Lpath, Inc. Improved anti-lysophospholipid antibody design using antibody structures
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2665814B1 (en) 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
WO2018197545A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
US20190083636A1 (en) * 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
US20220023430A1 (en) * 2018-11-13 2022-01-27 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
MX2022000285A (es) 2019-07-08 2022-02-03 Gi Innovation Inc Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo.
CN116249552A (zh) * 2020-08-11 2023-06-09 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
ES2115638T3 (es) 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
JP2747967B2 (ja) 1993-07-23 1998-05-06 雪印乳業株式会社 シアル酸粉末
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
WO1999043307A1 (en) 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) * 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
AU2001258536A1 (en) 2000-05-16 2001-11-26 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
JP5178982B2 (ja) 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001290312A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
AU3323002A (en) 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
MXPA05002594A (es) * 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
US9040664B2 (en) * 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
WO2004101619A1 (ja) 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
DE602004016170D1 (de) 2003-07-03 2008-10-09 Cipla Ltd Verfahren zur herstellung von finasterid form i
ATE345995T1 (de) 2003-08-05 2006-12-15 Dematic Corp Querantrieb für motorisierte rolle
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1660134B1 (en) 2003-08-08 2010-12-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and g-csf
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
NZ547168A (en) * 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
ES2422187T3 (es) * 2003-12-03 2013-09-09 Biogenerix Ag Factor estimulante de colonias de granulocitos glicopegilados
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP2336192A1 (en) * 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
EP1776389B1 (en) * 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
EP1789454B1 (en) 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionation of charged polysaccharide
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
JP2011037843A (ja) 2009-07-16 2011-02-24 Kao Corp 食後血中インスリン濃度上昇抑制剤
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Site-Specific Introduction of Sialic Acid into insulin;Sato M., et al.;《Angewandte Chemie International Edition》;20041231;第43卷(第12期);1516-1520 *

Also Published As

Publication number Publication date
US20140315802A1 (en) 2014-10-23
US8946406B2 (en) 2015-02-03
JP2015007062A (ja) 2015-01-15
US20150252090A1 (en) 2015-09-10
JP6581157B2 (ja) 2019-09-25
RU2432175C2 (ru) 2011-10-27
US20170119893A1 (en) 2017-05-04
JP2013100309A (ja) 2013-05-23
CN103169984A (zh) 2013-06-26
EP2043692B1 (en) 2016-05-18
WO2008012542A3 (en) 2008-05-15
ES2581902T3 (es) 2016-09-08
US9234020B2 (en) 2016-01-12
US8299026B2 (en) 2012-10-30
JP2013241446A (ja) 2013-12-05
US20180289823A1 (en) 2018-10-11
US9549990B2 (en) 2017-01-24
JP2009544681A (ja) 2009-12-17
RU2009105696A (ru) 2010-08-27
JP2018039791A (ja) 2018-03-15
JP2017018107A (ja) 2017-01-26
US20170058273A1 (en) 2017-03-02
US20100022441A1 (en) 2010-01-28
WO2008012542A8 (en) 2009-07-16
JP2009544680A (ja) 2009-12-17
WO2008012525A8 (en) 2010-04-29
US20160129124A1 (en) 2016-05-12
US20150147307A1 (en) 2015-05-28
JP6055506B2 (ja) 2016-12-27
WO2008012525A1 (en) 2008-01-31
US20130116176A1 (en) 2013-05-09
KR20090057370A (ko) 2009-06-05
EP2043693B1 (en) 2016-04-27
JP5912152B2 (ja) 2016-04-27
CN101511391B (zh) 2013-03-13
US8299015B2 (en) 2012-10-30
ATE467642T1 (de) 2010-05-15
US20220133898A1 (en) 2022-05-05
EP2043616B1 (en) 2016-01-27
US20100056427A1 (en) 2010-03-04
ES2344670T3 (es) 2010-09-02
US8796207B2 (en) 2014-08-05
JP5542195B2 (ja) 2014-07-09
US9266936B2 (en) 2016-02-23
JP5586669B2 (ja) 2014-09-10
US8981050B2 (en) 2015-03-17
US20100022443A1 (en) 2010-01-28
US20150158924A1 (en) 2015-06-11
US8933026B2 (en) 2015-01-13
CN101511391A (zh) 2009-08-19
JP5096466B2 (ja) 2012-12-12
JP2016128493A (ja) 2016-07-14
JP2015145400A (ja) 2015-08-13
JP2013049675A (ja) 2013-03-14
JP2009544678A (ja) 2009-12-17
US9474805B2 (en) 2016-10-25
JP5419689B2 (ja) 2014-02-19
US9492557B2 (en) 2016-11-15
EP2043692A2 (en) 2009-04-08
JP2009544677A (ja) 2009-12-17
US20170080054A1 (en) 2017-03-23
ES2569066T3 (es) 2016-05-06
US20140134147A1 (en) 2014-05-15
JP6243456B2 (ja) 2017-12-06
DE602007006492D1 (de) 2010-06-24
ES2581983T3 (es) 2016-09-08
JP2014114315A (ja) 2014-06-26
EP2043616A1 (en) 2009-04-08
JP5420091B2 (ja) 2014-02-19
JP6203342B2 (ja) 2017-09-27
EP3299033A1 (en) 2018-03-28
WO2008012540A9 (en) 2009-03-12
EP2630972B1 (en) 2017-08-30
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
JP5941440B2 (ja) 2016-06-29
US20160129123A1 (en) 2016-05-12
US20160095930A1 (en) 2016-04-07
US9492556B2 (en) 2016-11-15
US20140161765A1 (en) 2014-06-12
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
EP2041167B1 (en) 2010-05-12
EP2041167A1 (en) 2009-04-01
US20140309166A1 (en) 2014-10-16
EP2043693A1 (en) 2009-04-08
JP2013121982A (ja) 2013-06-20
WO2008012528A1 (en) 2008-01-31
US9789163B2 (en) 2017-10-17
US10300144B2 (en) 2019-05-28
EP2630972A3 (en) 2013-10-16
EP2630972A2 (en) 2013-08-28
WO2008012542A2 (en) 2008-01-31
ES2647528T3 (es) 2017-12-22
US9579393B2 (en) 2017-02-28
US20140309407A1 (en) 2014-10-16
WO2008012540A1 (en) 2008-01-31
JP6165079B2 (ja) 2017-07-19
US9040478B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
US20220133898A1 (en) Derivatisation of Insulin with Polysaccharides
Class et al. Patent application title: Derivatisation of Erythropoietin (EPO) Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Norbert Oskar Rumpf (London, GB) Norbert Oskar Rumpf (London, GB) Assignees: Lipoxen Technologies Limited

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160803

Termination date: 20210725